This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Generic Name
- Givinostat
- DrugBank Accession Number
- DB12645
- Background
Givinostat has been used in trials studying the treatment of Polycythemia Vera, Juvenile Idiopathic Arthritis, Duchenne Muscular Dystrophy (DMD), Chronic Myeloproliferative Neoplasms, and Polyarticular Course Juvenile Idiopathic Arthritis.
- Type
- Small Molecule
- Groups
- Investigational
- Structure
Structure for Givinostat (DB12645)
- Weight
- Average: 421.497
Monoisotopic: 421.200156361 - Chemical Formula
- C24H27N3O4
- Synonyms
- Givinostat
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug eventsImprove clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events & improve clinical decision support.- Pharmacodynamics
Not Available
- Mechanism of action
Target Actions Organism UHistone deacetylase inhibitorHumans - Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAcrivastine The risk or severity of QTc prolongation can be increased when Acrivastine is combined with Givinostat. Adenosine The risk or severity of QTc prolongation can be increased when Givinostat is combined with Adenosine. Ajmaline The risk or severity of QTc prolongation can be increased when Ajmaline is combined with Givinostat. Alfuzosin The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Givinostat. Alimemazine The risk or severity of QTc prolongation can be increased when Alimemazine is combined with Givinostat. Amantadine The risk or severity of QTc prolongation can be increased when Amantadine is combined with Givinostat. Amifampridine The risk or severity of QTc prolongation can be increased when Givinostat is combined with Amifampridine. Amiodarone The risk or severity of QTc prolongation can be increased when Givinostat is combined with Amiodarone. Amisulpride The risk or severity of QTc prolongation can be increased when Amisulpride is combined with Givinostat. Amitriptyline The risk or severity of QTc prolongation can be increased when Givinostat is combined with Amitriptyline. 
Identify potential medication risksEasily compare up to 40 drugs with our drug interaction checker.Get severity rating, description, and management advice.Learn more - Food Interactions
- Not Available
Categories
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as phenylcarbamic acid esters. These are ester derivatives of phenylcarbamic acids.
- Kingdom
- Organic compounds
- Super Class
- Benzenoids
- Class
- Benzene and substituted derivatives
- Sub Class
- Phenylcarbamic acid esters
- Direct Parent
- Phenylcarbamic acid esters
- Alternative Parents
- Naphthalenes / Benzoic acids and derivatives / Benzoyl derivatives / Aralkylamines / Carbamate esters / Trialkylamines / Organic carbonic acids and derivatives / Hydroxamic acids / Organopnictogen compounds / Organic oxides show 2 more
- Substituents
- Amine / Amino acid or derivatives / Aralkylamine / Aromatic homopolycyclic compound / Benzoic acid or derivatives / Benzoyl / Carbamic acid ester / Carbonic acid derivative / Carbonyl group / Carboxylic acid derivative show 12 more
- Molecular Framework
- Aromatic homopolycyclic compounds
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 5P60F84FBH
- CAS number
- 497833-27-9
- InChI Key
- YALNUENQHAQXEA-UHFFFAOYSA-N
- InChI
- InChI=1S/C24H27N3O4/c1-3-27(4-2)15-17-5-7-21-14-18(6-8-20(21)13-17)16-31-24(29)25-22-11-9-19(10-12-22)23(28)26-30/h5-14,30H,3-4,15-16H2,1-2H3,(H,25,29)(H,26,28)
- IUPAC Name
- {6-[(diethylamino)methyl]naphthalen-2-yl}methyl N-[4-(hydroxycarbamoyl)phenyl]carbamate
- SMILES
- CCN(CC)CC1=CC=C2C=C(COC(=O)NC3=CC=C(C=C3)C(=O)NO)C=CC2=C1
References
- General References
- Not Available
- External Links
- PubChem Compound
- 9804992
- PubChem Substance
- 347828853
- ChemSpider
- 7980752
- BindingDB
- 50105329
- ChEBI
- 94187
- ChEMBL
- CHEMBL1213492
- ZINC
- ZINC000003820616
- PDBe Ligand
- QCM
- Wikipedia
- Givinostat
- PDB Entries
- 6uoc
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 3 Completed Treatment Duchenne's Muscular Dystrophy (DMD) 1 2 Active Not Recruiting Treatment Chronic Myeloproliferative Neoplasms 1 2 Completed Treatment Active Systemic / Onset Juvenile Idiopathic Arthritis 1 2 Completed Treatment Becker's Muscular Dystrophy (BMD) 1 2 Completed Treatment Myeloproliferative Disorders (MPD) 1 2 Completed Treatment Polycythemia Vera (PV) 1 2 Terminated Treatment Chronic Lymphocytic Leukemia 1 2 Terminated Treatment Polyarticular Juvenile Idiopathic Arthritis 1 2, 3 Enrolling by Invitation Treatment Duchenne's Muscular Dystrophy (DMD) 1 1 Completed Treatment Drug Drug Interaction (DDI) 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.0052 mg/mL ALOGPS logP 4.18 ALOGPS logP 3.51 Chemaxon logS -4.9 ALOGPS pKa (Strongest Acidic) 9.99 Chemaxon pKa (Strongest Basic) 9.35 Chemaxon Physiological Charge 1 Chemaxon Hydrogen Acceptor Count 5 Chemaxon Hydrogen Donor Count 3 Chemaxon Polar Surface Area 90.9 Å2 Chemaxon Rotatable Bond Count 9 Chemaxon Refractivity 122.49 m3·mol-1 Chemaxon Polarizability 47.59 Å3 Chemaxon Number of Rings 3 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter Yes Chemaxon Veber's Rule No Chemaxon MDDR-like Rule Yes Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available
Targets
Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock newinsights and accelerate drug research.
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
- Kind
- Protein group
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Transcription regulatory region sequence-specific dna binding
- Specific Function
- Responsible for the deacetylation of lysine residues on the N-terminal part of the core histones (H2A, H2B, H3 and H4). Histone deacetylation gives a tag for epigenetic repression and plays an impo...
Components:
References
- Arya Y, Syal A, Gupta M, Gaba S: Advances in the Treatment of Polycythemia Vera: Trends in Disease Management. Cureus. 2021 Mar 30;13(3):e14193. doi: 10.7759/cureus.14193. [Article]
- Curreli F, Ahmed S, Victor SMB, Debnath AK: Identification of Combinations of Protein Kinase C Activators and Histone Deacetylase Inhibitors That Potently Reactivate Latent HIV. Viruses. 2020 Jun 3;12(6). pii: v12060609. doi: 10.3390/v12060609. [Article]
Drug created at October 20, 2016 23:24 / Updated at May 05, 2022 17:18